Standout Papers
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer (2005)
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial (2010)
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 (2007)
- Overview of the main outcomes in breast-cancer prevention trials (2003)
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen (2009)
- Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study (2010)
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer (2011)
- Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy (2010)
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V (2016)
Immediate Impact
6 by Nobel laureates 11 from Science/Nature 106 standout
Citing Papers
The neuroscience of cancer
2023 StandoutNature
Breast cancer
2021 Standout
Works of John Forbes being referenced
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
2019
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| John Forbes | 6627 | 8022 | 5839 | 201 | 16.1k | |
| Victor G. Vogel | 5350 | 7829 | 6557 | 167 | 15.7k | |
| Michael Baum | 5660 | 6168 | 3420 | 276 | 13.0k | |
| James N. Atkins | 4288 | 8174 | 3782 | 107 | 14.1k | |
| Beat Thürlimann | 9893 | 10662 | 5388 | 212 | 17.5k | |
| R. Jakesz | 5099 | 6980 | 2991 | 331 | 11.8k | |
| Judith M. Bliss | 4847 | 6711 | 1858 | 270 | 13.4k | |
| Henning T. Mouridsen | 6558 | 7858 | 2495 | 242 | 13.8k | |
| Paul D.P. Pharoah | 4706 | 6484 | 5883 | 336 | 19.2k | |
| Alan S. Coates | 11056 | 14199 | 4826 | 297 | 23.4k | |
| Vera J. Suman | 3511 | 6892 | 2192 | 270 | 14.4k |
All Works
Login with ORCID to disown or claim papers
Loading papers...